Eli Lilly and Company $LLY Shares Sold by Inscription Capital LLC

Key Points

• Inscription Capital cut its Eli Lilly stake by 27% in the third quarter, selling 1,116 shares and retaining 3,023 shares valued at about $3.5 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly beat quarterly estimates, reporting EPS of $7.48 versus $5.71 expected and revenue of $24.4 billion, up 38.6% year over year. The company also declared a quarterly dividend of $1.73 per share.
• Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating, with a consensus price target of $1,404.14. Meanwhile, executives reported selling shares under pre-arranged trading plans, and investors face concerns about GLP-1 price competition.

Inscription Capital LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 3,023 shares of the company's stock after selling 1,116 shares during the period. Inscription Capital LLC's holdings in Eli Lilly and Company were worth $3,497,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Marshall & Sterling Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after buying an additional 15 shares during the period. Torren Management LLC boosted its stake in shares of Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company's stock worth $37,000 after buying an additional 25 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth about $42,000. Foresight Capital Management Advisors Inc. acquired a new stake in Eli Lilly and Company during the third quarter worth about $49,000. Finally, Caitlin John LLC purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $64,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $17,020,770. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 3.5%

Shares of LLY opened at $1,368.85 on Friday. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.43, a PEG ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,453.00. The stock's 50 day moving average is $1,211.30 and its two-hundred day moving average is $1,099.50. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the prior year, the company posted $7.02 EPS. The business's quarterly revenue was up 38.6% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
• Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
• Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research report on Monday. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research note on Friday, October 30th. UBS Group raised their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Finally, Weiss Ratings lowered shares of Eli Lilly and Company from a "buy (b+)" rating to a "buy (b)" rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,404.14.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.